Chemomab Therapeutics Ltd.
CMMB
$1.20
-$0.02-1.64%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 3.48M | 5.81M | 7.08M | 11.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 16.03M | 20.46M | 25.46M | 32.26M |
| Operating Income | -- | -16.03M | -20.46M | -25.46M | -32.26M |
| Income Before Tax | -- | -15.05M | -19.36M | -24.22M | -31.81M |
| Income Tax Expenses | -- | -55.00K | -21.00K | 0.00 | -513.00K |
| Earnings from Continuing Operations | -- | -15.00 | -19.34 | -24.22 | -31.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -15.00M | -19.34M | -24.22M | -31.30M |
| EBIT | -- | -16.03M | -20.46M | -25.46M | -32.26M |
| EBITDA | -- | -15.97M | -20.39M | -25.39M | -32.20M |
| EPS Basic | -- | -22.68 | -31.98 | -42.38 | -55.51 |
| Normalized Basic EPS | -- | -0.32 | -0.61 | -1.11 | -1.76 |
| EPS Diluted | -- | -22.68 | -31.98 | -42.38 | -55.51 |
| Normalized Diluted EPS | -- | -0.32 | -0.61 | -1.11 | -1.76 |
| Average Basic Shares Outstanding | -- | 53.35M | 50.13M | 46.97M | 45.16M |
| Average Diluted Shares Outstanding | -- | 2.67M | 2.51M | 2.35M | 2.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |